Efficacy of fetal LAK cells in the treatment of advanced hepatocellular carcinoma

Qi Yanchao, Wang Yan, Wang Yanfang, Jiao Hong, Zhang Xiaomin, Shang Jia, Li Huaibin, Zhang Yanrui, Han Shuangyin, Liu Fusheng, Qiao Feng Gui, Jia Bailing

1. Henan Cancer Research Institute! Zhengzhou 4500032. Henan Cancer Research Institute! Zhengzhou 4500033. Henan Cancer Research Institute! Zhengzhou 4500034. Henan Cancer Research Institute! Zhengzhou 4500035. Henan Cancer Research Institute! Zhengzhou 4500036. Henan Provincial People's Hospital 7. Henan Provincial People's Hospital 8. Henan Provincial People's Hospital 9. Henan Provincial People's Hospital 10. Henan Provincial People's Hospital 11. Henan Provincial People's Hospital 12. Henan Provincial People's Hospital

From January 1989 to October 1991, fetal LAK cells were prepared by co-culture of fetal spleen cells and interleukin-2 (IL-2) for 3 days at the age of 6 to 7 months, and 18 cases of advanced liver cancer were treated by intravenous infusion or hepatic artery infusion. Results Pain relief in 16 cases, accounting for 88.9%; appetite increased in 14 cases, accounting for 77%; clinical complete remission in 2 cases, accounting for 11%; partial remission in 14 cases, accounting for 77%; total effective rate was 88.9%(16/18). And after LAK cell therapy in patients with peripheral blood OKT₄Rates elevated, OKT₈The ratio decreased, indicating that the patient's immune function has improved after treatment. The results suggest that: ① the fetal spleen contains abundant LAK precursor cells; ② the fetal LAK cells have obvious curative effect in the treatment of advanced liver cancer.

Key words:the fetus;LAK cells;Liver cancer;

• Album: Medical and Health Technology
• Special Topic: Oncology
• Classification number: R735.7

Observation on the curative effect of fetal LAK cells in the treatment of advanced liver cancer_Qi Yanchao. pdf